AstraZeneca
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
It remains to be seen how precision oncology drug and genetic test developers will improve representation of racial and ethnic minorities based on the agency's guidelines.
NICE Recommends AstraZeneca's Imfinzi for PD-L1-Positive NSCLC
The agency recommended that NHS England make the immunotherapy available based on data from the Phase III PACIFIC trial.
Strata Oncology Enrolling Patients in Basket Trial Exploring Biomarker-Defined Indications
The Strata PATH trial is exploring new precision oncology indications for already marketed drugs, including for four Pfizer treatments.
AstraZeneca Q1 Oncology Product Sales Increase 14 Percent Led by Tagrisso
Revenues from AstraZeneca's oncology segment in Q1 2022 totaled $3.64 billion, comprising around a third of the company's total revenues.